Pharmaceuticals
First procedure in Netherlands with NaoTrac surgical navigation robot is performed at Erasmus MC Rotterdam
HSINCHU, July 17, 2024 /PRNewswire/ -- Brain Navi announces the completion of its first case inNetherlands, which was successfully and safely performed at Erasmus MC inRotterdam, Netherlands. Brain biopsy helps doctors decide the best treatment for the patient after taking a tissue sample from t...
2024-07-17 15:49
3854
CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe
* CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at itsColorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry's most stringent quality and...
2024-07-17 10:16
3990
SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems
WILMINGTON, Del., July 16, 2024 /PRNewswire/ -- SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in princip...
2024-07-16 21:00
2100
Seegene Showcases HPV Diagnostic Kits and PCR Technology at AOGIN 2024
* Showcases Allplex™ HPV products designed to test for 14 high-risk HPV genotypes * Advocates HPV testing for early diagnosis and prevention of cervical cancer * Aims to accelerate the widespread adoption of syndromic PCR testing to create "a world free from all diseases" SEOUL, South Kore...
2024-07-16 21:00
3983
Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma
SINGAPORE, July 16, 2024 /PRNewswire/ -- Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) inChina has approved the initiation of a...
2024-07-16 17:10
3264
CPHI & PMEC Shenzhen 2024: Fostering New Opportunities in Asia and China's Greater Bay Area
SHANGHAI, July 15, 2024 /PRNewswire/ -- CPHI & PMEC China 2024 concluded in June with an exceptional turnout of visitors, setting a new attendance record. Notably, the number of international visitors grew to 11,563, and professionals from the end-to-end pharmaceutical supply chain made meaningfu...
2024-07-15 13:59
3681
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, July 15, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive topline data results of the ...
2024-07-15 13:44
3008
Basecare Medical (2170. HK) revenue growth exceeds 50% in 2024H1
SUZHOU, China , July 15, 2024 /PRNewswire/ -- Basecare Medical (2170. HK) released an unaudited interim performance forecast onJuly 12th, stating that the company's revenue for the first half of the year was approximatelyRMB 127 million to RMB 138 million, an increase of approximately 49% to 62% ...
2024-07-15 12:17
5628
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, an...
2024-07-12 16:53
6797
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric...
2024-07-11 14:24
3694
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
MELBOURNE, Australia, July 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments ...
2024-07-11 08:21
3067
Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut
PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists with a novel strategy to better understand how genes fro...
2024-07-10 23:00
2612
Cambrex to Expand Stability Storage Business with New Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., July 8, 2024 /PRNewswire/ -- Cambrex today announced the expansion of its stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device, and life sciences industries. Q1 Scientific will op...
2024-07-08 18:00
3562
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...
2024-07-08 14:30
5084
Olverembatinib Approved for Commercialization in Macau China
ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological malignancies, announced today that its novel BCR-ABL1 tyro...
2024-07-08 08:55
4454
Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility
SAN FRANCISCO and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Environmental, Social and Governance (ESG) criteria are key indicators of a company's long-term sustainability. Innovent Biologics has been actively addressing the United Nations' Sustainable Development Goals (SDGs) and recently launc...
2024-07-08 08:00
3811
FAIR PLAY MENARINI INTERNATIONAL AWARD, A MAGICAL NIGHT AT FIESOLE FOR THE GRAND FINALE
FLORENCE, Italy, July 5, 2024 /PRNewswire/ -- A finale to remember: the sporting legends delighted the packed terraces of the Roman Theatre in Fiesole, bringing the curtain down on the28th Fair Play Menarini International Award. Yesterday, the event dedicated to the values of ethics, loyalty, and...
2024-07-05 21:48
5148
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of ...
2024-07-05 21:18
9595
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
GAITHERSBURG, Md., July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-07-05 19:00
6207
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...
2024-07-05 16:30
6752
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
USSEC Advances Aquaculture Feed Formulation in Asia
[Picked up by 264 media titles]
2026-09-17 09:00
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
15057
Cheetah Mobile Announces Second Quarter 2026 Unaudited Consolidated Financial Results
2026-09-11 10:36
11291
